RxDoctor Payments Data

Sabrina Sandoval, MD

Psychiatry · Long Beach, CANPI 1538370721

Payments from drug & device makers

$10,988in general payments, 2019–2025

Across 522 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$895
  • Teva Pharmaceuticals USA, Inc.$820
  • Lundbeck LLC$629
  • plus $3K from 11 others

What the payments were for

  • Food & beverage$10,78398%
  • Education$2052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,988 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$285,235
Medicare patients
344
Services billed
2,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl45$283,047
AplenzinBupropion Hbr13$44,687
VraylarCariprazine Hcl14$29,575
RexultiBrexpiprazole21$29,539
AuvelityDextromethorphan Hbr/Bupropion15$16,432
Lurasidone Hcl13$5,229
Chlorpromazine Hcl28$2,780
Divalproex Sodium ErDivalproex Sodium32$1,242
Haloperidol Decanoate22$1,182
Olanzapine46$1,047
Eszopiclone30$936
Bupropion XlBupropion Hcl29$905
Hydroxyzine Hcl53$761
Aripiprazole13$575
Sertraline Hcl90$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$2,046$283,04745 claims
Bausch Health US, LLCAplenzin$585$44,68713 claims
AbbVieVraylar$2,123$29,57514 claims
Otsuka America Pharmaceutical, Inc.Rexulti$480$29,53921 claims
Axsome Therapeutics, Inc.Auvelity$265$16,43215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →